Qiagen

Bristol-Myers Squibb, QIAGEN ink NGS technology agreement

Monday, June 5, 2017

Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment. This will leverage the combination of Bristol-Myers Squibb’s portfolio of I-O therapies with QIAGEN’s proven track record in developing and commercializing companion and complementary diagnostics as well as QIAGEN’s portfolio of NGS technologies. I-O therapies offer a novel way to treat cancer by using drugs to target the body’s immune system to help fight cancer.

[Read More]

Companion diagnostics are here to stay

Monday, December 7, 2015

The Pulse on Global Trials by Matthew Howes

The story of personalized medicine has evolved from folklore to popular science, and is destined to become classic medical literature.

[Read More]

Qiagen launches clinical bioinformatics platform for next-generation sequencing

Wednesday, May 27, 2015

Qiagen, a Netherlands-based holding company, has launched its Qiagen Clinical Insight (QCI) bioinformatics content and software platform for clinical testing labs to interpret and report on genomic variants identified in next-generation sequencing (NGS). The first two supported applications for the bioinformatics platform are in oncology for somatic and hereditary cancer testing.

[Read More]

Qiagen, Tokai Pharmaceuticals partner

Wednesday, March 18, 2015

Qiagen, a Netherlands-based holding company, has partnered with Germany-based Tokai Pharmaceuticals to combine new circulating tumor cells (CTCs) technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai’s novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies demonstrated potential utility to guide therapy choice in CRPC patients.

[Read More]

Qiagen acquires Enzymatics’ Enzyme Solutions Unit

Tuesday, January 13, 2015

Qiagen, a Netherlands-based holding company, has acquired the Enzyme Solutions Unit of Enzymatics, a developer, manufacturer and OEM supplier of enzymes essential to driving the adoption of Next-Generation Sequencing (NGS) and other genetic analysis technologies in life sciences research and clinical healthcare.

[Read More]

Qiagen, Eli Lilly collaborate to co-develop companion diagnostics

Tuesday, June 3, 2014

Qiagen, a Netherlands-based holding company, is collaborating with Eli Lilly to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types. The agreement includes the development of tests that will be based on Qiagen’s multi-modal, multi-analyte Modaplex analysis platform, which can process multiple sample types and biomarkers in a single test.   

[Read More]